Results 211 to 220 of about 63,945 (289)

Observed and Patient‐Perceived Information Provision When Diagnosed With Parkinson's Disease

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background People with Parkinson's disease (PD) perceive to receive insufficient disease‐specific information after diagnosis, whereas clinicians report providing all relevant information. Objectives The objectives were to examine the information actually provided by clinicians during diagnostic consultations and its relations with background ...
Elisabeth Kurpershoek   +10 more
wiley   +1 more source

The Evolving Landscape of Immunotoxicity: Charting Mechanisms and Future Strategies for Immune Checkpoint Inhibitor Adverse Events

open access: yesMed Research, EarlyView.
ABSTRACT The use of immune checkpoint inhibitors (ICIs) has significantly improved the efficacy of cancer therapy, but their associated immune‐related adverse events (irAEs) can severely compromise treatment safety. This review systematically summarizes the core mechanisms underlying irAEs, which include multi‐organ damage resulting from T‐cell ...
Anqi Lin   +8 more
wiley   +1 more source

An Analysis Between Body Composition and Vertigo Post-Coronavirus Disease 2019 Patients. [PDF]

open access: yesInt Arch Otorhinolaryngol
Marchiori LLM   +4 more
europepmc   +1 more source

Digital Therapeutics for Alzheimer's and Parkinson's Diseases: Current Trends and Future Perspectives

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT Alzheimer's disease (AD) and Parkinson's disease (PD), which are characterized by the accumulation of misfolded protein aggregates and cognitive/motor dysfunction, are the most prevalent neurodegenerative diseases (NDDs). Despite strategic investigations aimed at augmenting the pharmaceutical pipeline, available drugs for AD and PD merely slow
Yoo Joo Jeong   +12 more
wiley   +1 more source

Upbeat-torsional nystagmus due to a small pontine hemorrhage: A case report. [PDF]

open access: yesMedicine (Baltimore)
Kimura M, Fujita H, Onuma H, Suzuki K.
europepmc   +1 more source

A Phase 1, Double‐Blind, Placebo‐Controlled Trial of Sevasemten (EDG‐5506), a Selective Modulator of Fast Skeletal Muscle Contraction, in Healthy Volunteers and Adults With Becker Muscular Dystrophy

open access: yesMuscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Sevasemten (EDG‐5506) is an orally administered, investigational small molecule that selectively modulates fast muscle fiber contraction by inhibiting fast myosin ATPase. This study assessed the safety, tolerability, and pharmacokinetics (PK)/pharmacodynamics (PD) of sevasemten in healthy adult volunteers (HVs) and adults ...
Joanne Donovan   +11 more
wiley   +1 more source

Utility and Challenges of Imaging in Peripheral Vestibular Disorder Diagnosis: A Narrative Review. [PDF]

open access: yesDiagnostics (Basel)
Musat GC   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy